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Recently, the American College of Cardiology (ACC) and the
American Heart Association (AHA) issued new guidelines on manage-
ment of cardiovascular (CV) risk in primary prevention.1 They devel-
oped a new CV risk calculator [new pooled cohort atherosclerotic
CV disease (CVD) risk equation] targeting individuals between
40 and 75 years and based on four American population-based
cohorts.2,3 Statin treatment is recommended for individuals with an
estimated 10-year risk of CVD ≥7.5%, including stroke. Conversely,
the guidelines of the European Society of Cardiology (ESC) advocate
the use of the SCORE equation for individuals aged between 40 and
65 years, and initiation of a statin treatment is recommended if the
estimated 10-year risk of death from CVD is≥5%.4 Whether applying
the ACC/AHA guidelines has similar public health consequences as
applying the ESC guidelines is currently unknown. Hence, we used
the data from a large, population-based study, to assess the country-
wide population and economic impact of these new guidelines,
supposing full adherence to treatment recommendations.
Data from the Swiss CoLaus study, collected between 2003 and
2006 in 3297 participants (1854 women) aged 50–75 years, were
used.5 Ten-year CVD risk was computed according to the Swiss
SCORE (ESC) and the 2013 ACC/AHA risk equations; results
were extrapolated to the Swiss population of the same age group.
The Swiss SCORE equation has been validated in individuals up to
75 years of age. Daily cost of treatment was estimated using one
widely used statin, i.e. atorvastatin.
The results are summarized in Table 1. Irrespective of the risk
equation used, the prevalence of high-risk individuals increased con-
siderably with age, exceeding 80% among participants aged over 70
years. Extrapolated to the Swiss population, applying the ACC/
AHA guidelines more than doubled the prevalence of high-risk
individuals (2.2-fold in men and 1.9 fold in women) relative to the
SCORE function. The biggest differences were observed for age
group 50–60 years, where the ACC/AHA guidelines led to a
30-fold increase in the number of high-risk individuals relative to
the ESC guidelines. Full compliance with the ACC/AHA guidelines
would also lead to an extra cost of treatment of 1.124 million CHF
per day (410 million CHF, or 333.7 million E, per year).
We conclude that, relative to the ESC guidelines, the 2013 ACC/
AHA guidelines lead to a considerable increase in the numberof high-
risk individuals susceptible of receiving statin treatment. This increase
is particularly strong in the age group 50–60 years. One likely explan-
ation for this discrepancy may be due to differences in the prevalence
of CV risk factors between the USA and Europe.6,7 Consequently, if
fully implemented, the ACC/AHA guidelines might lead to a con-
siderable increase in primary prevention costs of CVD. Further
studies are needed to validate the new ACC/AHA risk equation
and to assess the cost-effectiveness of the ACC/AHA guidelines in
non-US countries.
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Table 1 Simulations of the population impact and of daily costs related to treatment with atorvastatin in Switzerland
according to the European Society of Cardiology (ESC) or 2013 American College of Cardiology and the American Heart
Association (ACC/AHA) guidelines
Swiss population Population at riska Ratio ACC/AHA to ESCb Daily cost of treatmentc
ESC Men Women Total Men Women Total Men Women Total Atorvastatind
(50–60) 561 013 551 105 1 112 118 8976 — e 8976 — — — 13
(60–70) 429 528 448 861 878 389 204 026 29 176 233 202 — — — 350
(70–75) 176 448 205 307 381 755 175 389 181 491 356 881 — — — 536
All 1 814 130 1 841 332 3 655 462 388 391 210 667 599 059 — — — 899
ACC/AHA
(50–60) 561 013 551 105 1 112 118 274 335 23 698 298 033 30.6 NA 33.2 447
(60–70) 429 528 448 861 878 389 419 649 169 221 588 869 2.1 5.8 2.5 884
(70–75) 176 448 205 307 381 755 176 448 204 486 380 934 1.0 1.1 1.1 572
All 1 166 989 1 205 273 2 372 262 870 432 397 405 1 267 836 2.2 1.9 2.1 2023
aAccording to the ACC/AHA (new pooled cohort atherosclerotic CV disease risk equation) or ESC (Swiss SCORE equation) guidelines.
bRatio of the number of subjects at risk according to ACC/AHA guidelines to the number of subjects at risk according to ESC guidelines. NA, not assessable.
cExpressed in 1000 CHF. To obtain E, multiply by 0.814; to obtain USD, multiply by 1.110. Currency exchange rates as of 3 January 2014 were applied.
dFixed daily price independent of dosing (10–80 mg).
eSCORE equation do not predict CV risk for women under 60 years.
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